Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Psychedelic Compounds as Novel Anti-Epilepsy Therapies
EF 2023-24
Résumé
Psilocybin (Magic mushrooms), and lysergic acid diethylamide (LSD, acid) are psychedelic compounds with profound therapeutic benefit spanning an array of neurological and psychiatric conditions. The existing body of clinical literature has excluded individuals with a past or current history of seizures from partaking in clinical trials, leaving individuals with epilepsy out from receiving the the therapeutic benefits, even though they disproportionately experience mental health challenges. There is no clinical or preclinical literature indicating these substances exacerbate epileptic seizures. Thus, these substances may be safe for use in this population to treat the mental health co-morbidities. This project aims to establish the safety, and possibly anti-seizure properties of LSD and psilocybin in chronic and acute seizure models.
This project will be done in 2 arms for each drug.
Arm 1 will test LSD and psilocybin in mice with implanted intracranial electrodes in the neocortex and hippocampus area mid CA3. Other regions will be subsequently examined as well. The model of acute kainic acid (KA)-induced status epilepticus will be used. Two sub-trials will be done, using KA and LSD (trial 1) and psilocybin (trial 2). Each sub-trial will examine the effect of pre-treatment (30min or 24 hours) with a psychedelic on seizure severity and duration, as well as time to recovery.
Arm 2 will use acute mouse brain slices and human-derived cerebral organoids (hCOs) to test the anti-convulsant effect of LSD and psilocybin using electrophysiology local field potentials. a novel multi-eletrode array (MEA) system will be used to examine spreading depolarization and cross-frequency coupling in brain slices and hCOs to understand the biophysical effects of psychedelics.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506320
Name
Rabinovitch Brenden S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Psychedelic Compounds as Novel Anti-Epilepsy Therapies
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Behaviour; Electrophysiology; Epilepsy; Lsd; Neurobiology; Organoids; Psilocybin; Psychedelics; Seizures
Abstract
Psilocybin (Magic mushrooms), and lysergic acid diethylamide (LSD, acid) are psychedelic compounds with profound therapeutic benefit spanning an array of neurological and psychiatric conditions. The existing body of clinical literature has excluded individuals with a past or current history of seizures from partaking in clinical trials, leaving individuals with epilepsy out from receiving the the therapeutic benefits, even though they disproportionately experience mental health challenges. There is no clinical or preclinical literature indicating these substances exacerbate epileptic seizures. Thus, these substances may be safe for use in this population to treat the mental health co-morbidities. This project aims to establish the safety, and possibly anti-seizure properties of LSD and psilocybin in chronic and acute seizure models.
This project will be done in 2 arms for each drug.
Arm 1 will test LSD and psilocybin in mice with implanted intracranial electrodes in the neocortex and hippocampus area mid CA3. Other regions will be subsequently examined as well. The model of acute kainic acid (KA)-induced status epilepticus will be used. Two sub-trials will be done, using KA and LSD (trial 1) and psilocybin (trial 2). Each sub-trial will examine the effect of pre-treatment (30min or 24 hours) with a psychedelic on seizure severity and duration, as well as time to recovery.
Arm 2 will use acute mouse brain slices and human-derived cerebral organoids (hCOs) to test the anti-convulsant effect of LSD and psilocybin using electrophysiology local field potentials. a novel multi-eletrode array (MEA) system will be used to examine spreading depolarization and cross-frequency coupling in brain slices and hCOs to understand the biophysical effects of psychedelics.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rabinovitch, Brenden S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~